Cell
Volume 37, Issue 2, June 1984, Pages 367-379
Journal home page for Cell

Article
Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors

https://doi.org/10.1016/0092-8674(84)90367-2Get rights and content

Abstract

A high percentage of transgenic mice developing from eggs microinjected with plasmids containing the SV40 early region genes and a metallothionein fusion gene develop tumors within the choroid plexus. A line of mice has been established in which nearly every affected animal succumbs to this brain tumor. Thymic hypertrophy and kidney pathology are also observed in some mice. SV40 T-antigen mRNA and protein are readily detected in affected tissues; however, SV40 T-antigen gene expression is barely detectable in unaffected tissues or in susceptible tissues prior to overt pathology, suggesting that tumorigenesis depends upon activation of the SV40 genes. Comparison of DNA from tumor tissue (or cell lines derived from tumors) with DNA from unaffected tissues reveals structural rearrangements as well as changes in DNA methylation of the foreign DNA. The SV40 genes are frequently amplified in tumor tissue, which further indicates that their expression is intimately involved in tumorigenesis in transgenic mice.

References (53)

  • M. Perucho et al.

    Human-tumor-derived cell lines contain common and different transforming genes

    Cell

    (1981)
  • M.J. Sleigh et al.

    Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells

    Cell

    (1978)
  • J. Abramczuk

    Attempts of permanent introduction of SV40 genome into mouse gametes and early embryos

  • J. Abramczuk et al.

    Tumor induction by simian virus 40 in the mouse is controlled by long term persistence of the viral genome and the immune response of the host

    J. Virol.

    (1984)
  • J.M. Bishop

    Cellular oncogenes and retroviruses

    Ann. Rev. Biochem.

    (1983)
  • R.L. Brinster et al.

    Expression of a microinjected immunoglobulin gene in the spleen of transgenic mice

    Nature

    (1983)
  • W.W. Colby et al.

    Fragments of the simian virus 40 transforming gene facilitate transformation of rat embryo cells

  • S. Collins et al.

    Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line

    Nature

    (1982)
  • G.M. Cooper

    Cellular transforming genes

    Science

    (1982)
  • R. Dalla Favera et al.

    Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient

    Nature

    (1982)
  • G.T. Diamondopoulos

    Leukemia, lymphomas, and osteosarcoma induced in the Syrian golden hamster by simian virus 40

    Science

    (1972)
  • G.T. Diamondopoulos

    Incidence, latency and morphological types of neoplasms induced by simian virus 40 inoculated intravenously into hamsters of three inbred strains and one outbred stock

    J. Nat. Cancer Inst.

    (1978)
  • M. Fried

    Cell transforming ability of a temperature sensitive mutant of polyoma virus

  • M. Groudine et al.

    Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation

    Nature

    (1981)
  • K. Harbers et al.

    Microinjection of cloned retroviral genomes into mouse zygotes: integration and expression in the animal

    Nature

    (1981)
  • E. Harlow et al.

    Monoclonal antibodies specific for SV40 tumor antigens

    J. Virol.

    (1981)
  • Cited by (402)

    • Preclinical models and technologies to advance nanovaccine development

      2021, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Genetic and biotechnology advances for nearly four decades enabled the development of precise GEMM, carrying specific aberrations present in human malignancies [274,275]. GEMM can be generated by different technologies, namely by using i) tissue-specific promoters to drive the expression of an oncogene (e.g., simian virus 40 (SV40) large T antigen [276–278]) or oncogenes related to tumor development (e.g., Kras [279–281], MYC [282,283], epidermal growth factor receptor (EGFR) [284] and BRAF V600E [285,286])), or ii) recombinase enzymes, such as Tet-on/off [281,287,288], tamoxifen-inducible Cre recombinase [289,290] and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology that eliminate tumor suppressor genes (e.g. TP53 [291–293], adenomatous polyposis coli (APC) [292,294], and phosphatase and tensin homolog (PTEN)) [291,292,294]. Contrarily to the previous tumor models, tumors in GEMM develop spontaneously in a tissue-specific manner, which mimic more closely the natural tumor development and progression, and therefore also harbor a TME similar to the human malignancies.

    • Animal models of primary brain tumors

      2019, Animal Models in Cancer Drug Discovery
    • Animal models of brain tumor surgery

      2019, Comprehensive Overview of Modern Surgical Approaches to Intrinsic Brain Tumors
    • A new genetically engineered mouse model of choroid plexus carcinoma

      2018, Biochemical and Biophysical Research Communications
    • Modeling Cancer Using CRISPR-Cas9 Technology

      2017, Animal Models for the Study of Human Disease: Second Edition
    View all citing articles on Scopus
    View full text